Summary
The aim of this study was to determine whether insulin sensitivity measured by the euglycaemic insulin clamp technique is lower in patients with primary hypertension than in matched healthy control subjects, and whether this sensitivity was affected after 12 weeks of antihypertensive treatment with the alpha 1-adrenoceptor blocking drug prazosin. Twelve moderately obese normoglycaemic patients (four men), with hypertension not previously treated with pharmacological agents and diastolic blood pressure above 100 mm Hg, and 12 healthy matched control subjects participated. Supine blood pressure decreased 12/5 mmHg (p<0.01) and standing blood pressure 14/9 mmHg (p=0.001) during prazosin treatment (mean dosage 5.3±1.6 mg/day (SD)). During euglycaemic insulin clamp studies the control subjects showed a higher mean glucose uptake than the untreated hypertensive patients (7.5±1.0 and 5.8±1.9 mg·kg b.w.−1·min−1, respectively, p<0.01). During prazosin treatment there was no significant difference between the hypertensive patients and the control subjects in this respect (6.6±2.8 and 7.5±1.0, respectively, p=0.21). During prazosin treatment, however, the disappearance rate of glucose decreased during the intravenous glucose tolerance test (from 1.7±0.9 to 1.3±0.6, p<0.02) and the area under the glucose concentration-time curve decreased by 38% (from 473±119 to 294±99, p<0.001). The peak insulin concentration decreased from 55±35 to 46±32 mU/l (p<0.006) and the area under the insulin concentration-time curve was suppressed by 38% (from 2368±1597 to 1479±940, p<0.01). This study shows that treatment of moderately obese hypertensive patients with prazosin is associated with an increase of the insulin-mediated glucose disposal and a decrease of the insulin response to an intravenous glucose load.
Article PDF
Similar content being viewed by others
References
Kahn CR (1980) Role of insulin receptors in insulin-resistant states. Metabolism 29: 455–466
Olefsky JM (1981) Insulin resistance and insulin action. An in vitro and in vivo perspective. Diabetes 30: 148–162
Reaven GM (1980) Insulin-independent diabetes mellitus: metabolic characteristics. Metabolism 29: 445–451
Lucas CP, Estigarribia JA, Darga LL, Reaven GM (1985) Insulin and blood pressure in obesity. Hypertension 7: 702–706
Berglund G, Larson B, Andersson O, Larsson O, Svärdsudd K, Björntorp P, Wilhelmsen L (1976) Body composition and glucose metabolism in hypertensive middle-aged males. Acta Med Scand 200: 163–169
DeFronzo RA (1981) The effect of insulin on renal sodium metabolism. Diabetologia 21: 165–171
Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L (1981) Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 30: 219–225
Basarab A, Silva P, Landsberg L (1979) Effect of catecholamines on tubular function in the isolated perfused rat kidney. J Clin Invest 64: 850–857
Winquist RJ, Webb RC, Bohr DF (1982) Vascular smooth muscle in hypertension. Fed Proc 41: 2387–2393
Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, Shitrit A, Fuchs Z (1985) Hyperinsulinemia; a link between hypertension, obesity and glucose intolerance. J Clin Invest 75: 809–827
Manicardi V, Camelline L, Bellodi G, Coscelli C, Ferrannini E (1986) Evidence for an association of high blood pressure and hyperinsulinemia in obese man. J Clin Endocrinol Metab 62: 1302–1304
Sowers JR, Nyby M, Stern N, Beck F, Baron S, Catania R, Vlachis N (1982) Blood pressure and hormone changes associated with weight reduction in the obese. Hypertension 4: 686–691
Lithell H, Berne C, Waern U, Wibell L (1985) Glucose metabolism during long-term treatment with prazosin. Diab Res 2: 297–299
Ikkos D, Luft R (1957) On the intravenous glucose tolerance test. Acta Endocr (Kbh) 25: 312–334
Jeppsson JO, Jerntorp P, Sundkvist G, Englund H, Nylund V (1986) Measurement of hemoglobin A1 C by a new liquid-chromatographic assay: methodology, clinical utility, and relation to glucose tolerance evaluated. Clin Chem 32: 1867–1872
Siegler L, Wu WT (1981) Separation of serum high-density lipoprotein for cholesterol determination: ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride. Clin Chem 27: 838–841
DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237: 214–233
McGuire EAM, Helderman JH, Tobin JD, Andres R, Berman M (1976) Effects of arterial versus venous sampling. An analysis of glucose kinetics in man. J Appl Physiol 41: 565–573
Bratusch-Marrain PR, Smith D, DeFronzo RA (1982) The effect of growth hormone on glucose metabolism and insulin secretion in man. J Clin Endocrinol Metab 55: 973–982
Rizza RA, Mandarino LJ, Gerich JE (1981) Mechanism and significance of insulin resistance in non-insulin dependent diabetes mellitus. Diabetes 30: 990–995
Rizza RA, Mandarino LJ, Gerich JE (1981) Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol 240: E630-E639
Bergman RN, Finegood DT, Ader M (1985) Assessment of insulin sensitivity in vivo. Endocr Rev 6: 45–86
DeFronzo RA, Ferrannini E, Hendler R, Felig P, Wahren J (1983) Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man. Diabetes 32: 35–45
Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S (1987) Insulin resistance in essential hypertension. N Engl J Med 317: 350–357
Doberne L, Greenfield MS, Rosenthal M, Widstrom A, Reaven G (1982) Effect of variations in basal plasma glucose concentration on glucose utilization (M) and metabolic clearance (MCR) rates during insulin clamp studies in patients with non-insulin-dependent diabetes mellitus. Diabetes 31: 396–400
Liu G, Chen I, Hollenbeck CB, Lardinois CK, Reaven GM (1984) Insulin-stimulated glucose disposal increases with time in patients with non-insulin-dependent diabetes mellitus. Diabetes 33: 643–647
Nakaki T, Nakadate T, Kato R (1980) Alpha2-adrenoceptors modulating insulin release from isolated pancreatic islets. Naunyn Schmiedebergs Arch Pharmacol 313: 151–153
Nakadate T, Nakaki T, Muraki T, Kato R (1980) Adrenergic regulation of blood glucose levels: possible involvement of postsynaptic alpha2-type adrenergic receptors regulating insulin release. J Pharmacol Exp Ther 215: 226–230
Scharf SC, Lee H-B, Wexler JP, Blaufox MD (1984) Cardiovascular consequences of primary antihypertensive therapy with prazosin hydrochloride. Am J Cardiol 53: 32A-36A
Koshy MC, Mickley D, Bourgoignio J, Blaufox MD (1977) Physical evaluation of a new antihypertensive agent: prazosin HCL. Circulation 55: 533–537
Ibsen H, Rasmussen K, Jensen HA, Leth A (1978) Changes in plasma volume and extracellular fluid volume after addition of prazosin to propranolol treatment in patients with hypertension. Scand J Clin Lab Invest 38: 425–429
Leren P, Foss OP, Helgeland A, Holme I, Lund-Larsen PG (1980) Effect of propranolol and prazosin on blood lipids. The Oslo Study. Lancet II: 4–6
Lowenstein J, Neusy A-J (1984) Effects of prazosin and propranolol on serum lipids in patients with essential hypertension. Am J Med 76: 79–84
Waldo R (1979) Prazosin relieves Raynaud's vasospasm. JAMA 241: 1037
Westheim A, Koss A, Sivertssen E (1986) Hemodynamic effects at rest and during exercise in long-term treatment witzh prazosin in chronic congestive heart failure. Acta Med Scand 219: 449–453
Jauch KW, Hartl W, Guenther B, Wicklmayr M, Rett K, Dietze G (1987) Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 17: 448–454
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pollare, T., Lithell, H., Selinus, I. et al. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 31, 415–420 (1988). https://doi.org/10.1007/BF00271585
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00271585